{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:07:04Z","timestamp":1764090424253,"version":"3.45.0"},"reference-count":80,"publisher":"Oxford University Press (OUP)","issue":"23","license":[{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD) is a genetic disorder caused by a mutation in the \u03b2-globin gene, leading to the production of abnormal sickle hemoglobin (HbS). This clinical consultation explores the pivotal role of hydroxyurea as a disease-modifying therapy in SCD and examines how pharmacist-led interventions can optimize its use to improve patient outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Hydroxyurea increases fetal hemoglobin (HbF) production, reducing HbS polymerization and lowering the frequency of vaso-occlusive crises, acute chest syndrome, and other complications. Despite its proven efficacy, barriers such as poor adherence, inadequate patient education, and suboptimal dosing hinder its effective use. Pharmacists, as integral members of the multidisciplinary care team, are ideally positioned to address these challenges. By providing patient education, regular laboratory monitoring, and dose titration to the maximum tolerated dose (MTD), pharmacists can enhance hydroxyurea\u2019s therapeutic benefits. Studies have shown that pharmacist-managed protocols significantly improve adherence, increase the proportion of patients achieving MTD, and lead to better clinical outcomes, such as higher HbF levels and fewer hospitalizations. Although emerging treatments such as gene therapies offer promise, hydroxyurea remains the most accessible and effective option for many patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pharmacists play a crucial role in optimizing hydroxyurea therapy for patients with SCD by improving adherence and maximizing dosing strategies. Their involvement ensures that more patients experience the full therapeutic benefits of hydroxyurea, contributing to better long-term outcomes. Expanding pharmacist engagement in SCD management will continue to be essential, particularly as new treatments are developed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf114","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T07:57:46Z","timestamp":1746259066000},"page":"e936-e945","source":"Crossref","is-referenced-by-count":0,"title":["Clinical consultation: The pharmacist\u2019s role in hydroxyurea management for sickle cell disease"],"prefix":"10.1093","volume":"82","author":[{"given":"Cameron","family":"Roessner","sequence":"first","affiliation":[{"name":"Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Center , Calgary, AB"},{"name":"Pharmacy Services, Foothills Medical Center , Calgary, AB ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Uminski","sequence":"additional","affiliation":[{"name":"Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Center , Calgary, AB"},{"name":"Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary , Calgary, AB ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dawn","family":"Goodyear","sequence":"additional","affiliation":[{"name":"Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Center , Calgary, AB"},{"name":"Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary , Calgary, AB ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Rydz","sequence":"additional","affiliation":[{"name":"Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, Foothills Medical Center , Calgary, AB"},{"name":"Division of Hematology and Hematological Malignancies, Department of Medicine, University of Calgary , Calgary, AB ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,12]]},"reference":[{"key":"2025112512014423500_CIT0001","first-page":"585","article-title":"Pathobiology of sickle cell disease","volume-title":"Hematology: Basic Principles and Practice","author":"Hebbel","year":"2023","edition":"8th ed"},{"issue":"10091","key":"2025112512014423500_CIT0002","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"Ware","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"2025112512014423500_CIT0003","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjh.13477","article-title":"How I manage cerebral vasculopathy in children with sickle cell disease","volume":"170","author":"Brousse","year":"2015","journal-title":"Br J Haematol"},{"issue":"8","key":"2025112512014423500_CIT0004","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000\u20132021: a systematic analysis from the Global Burden of Disease Study 2021","volume":"10","author":"Thomson","year":"2023","journal-title":"Lancet Haematol"},{"issue":"4 suppl","key":"2025112512014423500_CIT0005","doi-asserted-by":"crossref","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S","volume":"38","author":"Hassell","year":"2010","journal-title":"Am J Prev Med"},{"issue":"11","key":"2025112512014423500_CIT0006","doi-asserted-by":"publisher","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","article-title":"Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease","volume":"2","author":"Lubeck","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"23","key":"2025112512014423500_CIT0007","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease\u2014life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"key":"2025112512014423500_CIT0008","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pediatrneurol.2019.02.018","article-title":"Sickle cell disease and stroke","volume":"95","author":"Hirtz","year":"2019","journal-title":"Pediatr Neurol"},{"issue":"1","key":"2025112512014423500_CIT0009","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"issue":"25","key":"2025112512014423500_CIT0010","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM200006223422502","article-title":"Causes and outcomes of the acute chest syndrome in sickle cell disease","volume":"342","author":"Vichinsky","year":"2000","journal-title":"N Engl J Med"},{"key":"2025112512014423500_CIT0011","first-page":"599","article-title":"Clinical aspects of sickle cell disease","volume-title":"Hematology: Basic Principles and Practice","author":"Menapace","year":"2023","edition":"8th ed"},{"issue":"3","key":"2025112512014423500_CIT0012","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1182\/blood-2005-10-009506","article-title":"Stroke prevention trial in sickle cell anemia (STOP): extended follow-up and final results","volume":"108","author":"Lee","year":"2006","journal-title":"Blood"},{"key":"2025112512014423500_CIT0013","doi-asserted-by":"publisher","first-page":"S398","DOI":"10.1016\/j.amepre.2011.09.013","article-title":"Sickle cell disease in Africa: a neglected cause of early childhood mortality","volume":"41","author":"Grosse","year":"2011","journal-title":"Am J Prev Med"},{"issue":"17","key":"2025112512014423500_CIT0014","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"issue":"1","key":"2025112512014423500_CIT0015","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2011-03-325258","article-title":"Fetal hemoglobin in sickle cell anemia","volume":"118","author":"Akinsheye","year":"2011","journal-title":"Blood"},{"issue":"20","key":"2025112512014423500_CIT0016","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"11","key":"2025112512014423500_CIT0017","doi-asserted-by":"publisher","first-page":"e038685","DOI":"10.1136\/bmjopen-2020-038685","article-title":"Implementation of the therapeutic use of hydroxyurea for sickle cell disease management in resource-constrained settings: a systematic review of adoption, cost and acceptability","volume":"10","author":"Ryan","year":"2020","journal-title":"BMJ Open"},{"issue":"11","key":"2025112512014423500_CIT0018","doi-asserted-by":"publisher","first-page":"e2344546","DOI":"10.1001\/jamanetworkopen.2023.44546","article-title":"Use of disease-modifying treatments in patients with sickle cell disease","volume":"6","author":"Newman","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"13","key":"2025112512014423500_CIT0019","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1056\/NEJMct0708272","article-title":"Hydroxyurea for the treatment of sickle cell anemia","volume":"358","author":"Platt","year":"2008","journal-title":"N Engl J Med"},{"issue":"13","key":"2025112512014423500_CIT0020","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"2025112512014423500_CIT0021","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ajh.21699","article-title":"The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up","volume":"85","author":"Steinberg","year":"2010","journal-title":"Am J Hematol"},{"issue":"12","key":"2025112512014423500_CIT0022","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1182\/blood-2009-05-221333","article-title":"The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)","volume":"115","author":"Voskaridou","year":"2010","journal-title":"Blood"},{"issue":"5","key":"2025112512014423500_CIT0023","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1182\/blood.V94.5.1550","article-title":"Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I\/II trial","volume":"94","author":"Kinney","year":"1999","journal-title":"Blood"},{"issue":"9778","key":"2025112512014423500_CIT0024","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"2025112512014423500_CIT0025","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for children with sickle cell anemia in sub-Saharan Africa","volume":"380","author":"Tshilolo","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"2025112512014423500_CIT0026","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJM199202273260905","article-title":"The use of transcranial ultrasonography to predict stroke in sickle cell disease","volume":"326","author":"Adams","year":"1992","journal-title":"N Engl J Med"},{"issue":"10019","key":"2025112512014423500_CIT0027","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial Doppler flow velocities in children with sickle cell anaemia\u2014TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"2025112512014423500_CIT0028","doi-asserted-by":"publisher","first-page":"e261","DOI":"10.1016\/S2352-3026(22)00405-7","article-title":"Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial","volume":"10","author":"Ambrose","year":"2023","journal-title":"Lancet Haematol"},{"article-title":"Hydroxyurea toxicity","year":"2023","author":"Jinna","key":"2025112512014423500_CIT0029"},{"issue":"5","key":"2025112512014423500_CIT0030","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/phar.2792","article-title":"Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: a summary of the evidence, opportunities, and challenges","volume":"43","author":"Dexter","year":"2023","journal-title":"Pharmacotherapy"},{"issue":"6","key":"2025112512014423500_CIT0031","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1182\/blood-2003-07-2475","article-title":"Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease","volume":"103","author":"Zimmerman","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2025112512014423500_CIT0032","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/ajh.26495","article-title":"Pregnancy outcomes with hydroxyurea use in women with sickle cell disease","volume":"97","author":"Kroner","year":"2022","journal-title":"Am J Hematol"},{"issue":"3","key":"2025112512014423500_CIT0033","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1586\/ehm.10.22","article-title":"Hydroxyurea use in sickle cell disease: the battle with low rates of prescription, poor patient compliance, and fears of toxicities and side effects","volume":"3","author":"Brandow","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2025112512014423500_CIT0034","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2020008146","article-title":"Hydroxyurea does not affect the spermatogonial pool in prepubertal patients with sickle cell disease","volume":"137","author":"Gille","year":"2021","journal-title":"Blood"},{"issue":"6","key":"2025112512014423500_CIT0035","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood.2020006270","article-title":"Effect of hydroxyurea exposure before puberty on sperm parameters in males with sickle cell disease","volume":"137","author":"Joseph","year":"2021","journal-title":"Blood"},{"year":"2023","author":"World Health Organization","key":"2025112512014423500_CIT0036"},{"year":"2023","author":"World Health Organization","key":"2025112512014423500_CIT0037"},{"issue":"3","key":"2025112512014423500_CIT0038","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.hemonc.2018.01.001","article-title":"Beliefs about hydroxyurea in youth with sickle cell disease","volume":"11","author":"Badawy","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"5-6","key":"2025112512014423500_CIT0039","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/08880018.2018.1505988","article-title":"Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease","volume":"35","author":"Badawy","year":"2018","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"2025112512014423500_CIT0040","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1002\/ajh.21968","article-title":"Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease","volume":"86","author":"Candrilli","year":"2011","journal-title":"Am J Hematol"},{"issue":"1","key":"2025112512014423500_CIT0041","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/ajh.26765","article-title":"Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease","volume":"98","author":"Kang","year":"2023","journal-title":"Am J Hematol"},{"issue":"11","key":"2025112512014423500_CIT0042","doi-asserted-by":"publisher","first-page":"e224780","DOI":"10.1001\/jamahealthforum.2022.4780","article-title":"Too few children, teens with sickle cell anemia receive screening, medication to prevent serious complications","volume":"3","author":"Stephenson","year":"2022","journal-title":"JAMA Health Forum"},{"issue":"6","key":"2025112512014423500_CIT0043","doi-asserted-by":"publisher","first-page":"e0304644","DOI":"10.1371\/journal.pone.0304644","article-title":"Study protocol for ADHERE (Applying Directly observed therapy to HydroxyurEa to Realize Effectiveness): using small business partnerships to deliver a scalable and novel hydroxyurea adherence solution to youth with sickle cell disease","volume":"19","author":"Walden","year":"2024","journal-title":"PLoS One"},{"issue":"9","key":"2025112512014423500_CIT0044","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss7109a1","article-title":"Surveillance for sickle cell disease\u2014Sickle Cell Data Collection Program, two states, 2004\u20132018","volume":"71","author":"Snyder","year":"2022","journal-title":"MMWR Surveill Summ"},{"issue":"6","key":"2025112512014423500_CIT0045","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1111\/ejh.12878","article-title":"Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease","volume":"98","author":"Badawy","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"2025112512014423500_CIT0046","doi-asserted-by":"publisher","first-page":"2122056","DOI":"10.1155\/2022\/21220561","article-title":"Health-related quality of life and adherence to hydroxyurea and other disease-modifying therapies among individuals with sickle cell disease: a systematic review","volume":"2022","author":"Yang","year":"2022","journal-title":"BioMed Res Int"},{"article-title":"Consensus statement on the care of patients with sickle cell disease in Canada","year":"2024","author":"CanHaem Sickle Cell Disease Working Group","key":"2025112512014423500_CIT0047"},{"issue":"1","key":"2025112512014423500_CIT0048","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/asheducation-2015.1.436","article-title":"Optimizing hydroxyurea therapy for sickle cell anemia","volume":"2015","author":"Ware","year":"2015","journal-title":"Hematology"},{"volume-title":"Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014","year":"2014","author":"National Heart, Lung, and Blood Institute","key":"2025112512014423500_CIT0049"},{"issue":"10","key":"2025112512014423500_CIT0050","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"6","key":"2025112512014423500_CIT0051","doi-asserted-by":"publisher","first-page":"e425","DOI":"10.1016\/S2352-3026(24)00078-4","article-title":"Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1\/2 trial","volume":"11","author":"Aygun","year":"2024","journal-title":"Lancet Haematol"},{"issue":"26","key":"2025112512014423500_CIT0052","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1056\/NEJMoa2000146","article-title":"Hydroxyurea dose escalation for sickle cell anemia in sub-Saharan Africa","volume":"382","author":"John","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"2025112512014423500_CIT0053","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/phar.1834","article-title":"Impact of a clinical pharmacy service on the management of patients in a sickle cell disease outpatient center","volume":"36","author":"Han","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"1","key":"2025112512014423500_CIT0054","doi-asserted-by":"publisher","first-page":"4753349","DOI":"10.1155\/2024\/4753349","article-title":"A pharmacist-managed hydroxyurea prescribing protocol improves uptake and optimization among patients with sickle cell disease","volume":"2024","author":"Roessner","year":"2024","journal-title":"Adv Hematol"},{"issue":"1","key":"2025112512014423500_CIT0055","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1186\/s12913-018-3665-x","article-title":"Impact of pharmacy services on initial clinical outcomes and medication adherence among veterans with uncontrolled diabetes","volume":"18","author":"Gatwood","year":"2018","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"2025112512014423500_CIT0056","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1186\/s12913-021-06979-z","article-title":"Pharmacist-led intervention in treatment non-adherence and associated direct costs of management among ambulatory patients with type 2 diabetes in southwestern Nigeria","volume":"21","author":"Ipingbemi","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"2025112512014423500_CIT0057","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s11096-010-9474-x","article-title":"Pharmacist intervention program to enhance hypertension control: a randomised controlled trial","volume":"33","author":"Morgado","year":"2011","journal-title":"Int J Clin Pharm"},{"issue":"5","key":"2025112512014423500_CIT0058","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/jcpt.12185","article-title":"A multifaceted pharmacist intervention to improve antihypertensive adherence: a cluster-randomized, controlled trial (HAPPy trial)","volume":"39","author":"Stewart","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"2025112512014423500_CIT0059","doi-asserted-by":"publisher","first-page":"108037","DOI":"10.1016\/j.pec.2023.108037","article-title":"Effectiveness of clinical pharmacist intervention on medication adherence in patients with chronic obstructive pulmonary disease\u2014a randomized controlled study","volume":"118","author":"Nguyen","year":"2024","journal-title":"Patient Educ Couns"},{"issue":"6","key":"2025112512014423500_CIT0060","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1177\/08971900221118232","article-title":"Improvement in clinical outcomes and access to care with pharmacist-led chronic care management services at a rural family medicine clinic","volume":"36","author":"Tenpas","year":"2023","journal-title":"J Pharm Pract"},{"issue":"4","key":"2025112512014423500_CIT0061","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.japh.2021.02.014","article-title":"Clinical impact of a pharmacist + health coach chronic disease management program in a rural free clinic","volume":"61","author":"Hurst","year":"2021","journal-title":"J Am Pharm Assoc"},{"issue":"4","key":"2025112512014423500_CIT0062","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.18549\/PharmPract.2017.04.1134","article-title":"Pharmacists providing care in the outpatient setting through telemedicine models: a narrative review","volume":"15","author":"Littauer","year":"2017","journal-title":"Pharm Pract"},{"issue":"13","key":"2025112512014423500_CIT0063","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2146\/ajhp170633","article-title":"Impact of the clinical pharmacy specialist in telehealth primary care","volume":"75","author":"Litke","year":"2018","journal-title":"Am J Health-Syst Pharm"},{"issue":"12","key":"2025112512014423500_CIT0064","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/pbc.26161","article-title":"Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use","volume":"63","author":"Green","year":"2016","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"2025112512014423500_CIT0065","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/jac5.1516","article-title":"A pharmacist-led initiative for the management of hydroxyurea therapy in pediatric sickle cell anemia patients attending a multidisciplinary tertiary hemoglobinopathy clinic: a retrospective cohort study (PHARMIT-SCA)","volume":"4","author":"Barton","year":"2021","journal-title":"J Am Coll Clin Pharm"},{"author":"Yager","key":"2025112512014423500_CIT0066","article-title":"The effect of a novel pharmacist-run sickle cell management clinic"},{"issue":"5","key":"2025112512014423500_CIT0067","doi-asserted-by":"publisher","first-page":"e20182218","DOI":"10.1542\/peds.2018-2218","article-title":"Improving care for sickle cell pain crisis using a multidisciplinary approach","volume":"143","author":"Balsamo","year":"2019","journal-title":"Pediatrics"},{"issue":"18","key":"2025112512014423500_CIT0068","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"2025112512014423500_CIT0069","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"2025112512014423500_CIT0070","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40273-024-01385-9","article-title":"Cost-effectiveness of lovotibeglogene autotemcel (Lovo-Cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States","volume":"42","author":"Herring","year":"2024","journal-title":"PharmacoEconomics"},{"issue":"3","key":"2025112512014423500_CIT0071","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"8","key":"2025112512014423500_CIT0072","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1182\/blood.2023022193","article-title":"Novel therapeutic approaches in thalassemias, sickle cell disease, and other red cell disorders","volume":"144","author":"Pinto","year":"2024","journal-title":"Blood"},{"year":"2018","author":"European Medicines Agency","key":"2025112512014423500_CIT0073"},{"issue":"6","key":"2025112512014423500_CIT0074","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"key":"2025112512014423500_CIT0075","doi-asserted-by":"publisher","first-page":"q2147","DOI":"10.1136\/bmj.q2147","article-title":"Sickle cell drug is withdrawn over safety concerns just months after rollout","volume":"387","author":"Mahase","year":"2024","journal-title":"BMJ"},{"year":"2022","author":"Pfizer","key":"2025112512014423500_CIT0076"},{"issue":"5","key":"2025112512014423500_CIT0077","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025112512014423500_CIT0078","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1182\/blood-2023-185429","article-title":"Efficacy, safety, and biomarker analysis of 5\u00a0mg and 7.5\u00a0mg doses of crizanlizumab in patients with sickle cell disease: primary analyses from the phase III STAND study","volume":"142","author":"Abboud","year":"2023","journal-title":"Blood"},{"year":"2023","author":"Novartis","key":"2025112512014423500_CIT0079"},{"year":"2024","author":"Sickle Cell Society","key":"2025112512014423500_CIT0080"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf114\/63478405\/zxaf114.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/23\/e936\/63478405\/zxaf114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/82\/23\/e936\/63478405\/zxaf114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T17:01:50Z","timestamp":1764090110000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/82\/23\/e936\/8160995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":80,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2025,6,12]]},"published-print":{"date-parts":[[2025,11,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf114","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"type":"print","value":"1079-2082"},{"type":"electronic","value":"1535-2900"}],"subject":[],"published-other":{"date-parts":[[2025,12,1]]},"published":{"date-parts":[[2025,6,12]]}}}